We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

CODA Genomics Closes $1.6 Million Series B Financing

CODA Genomics Closes $1.6 Million Series B Financing

CODA Genomics Closes $1.6 Million Series B Financing

CODA Genomics Closes $1.6 Million Series B Financing

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "CODA Genomics Closes $1.6 Million Series B Financing"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

CODA Genomics, Inc. has announced that it has closed a Series B funding of over $1.6 million. The round was led by the Life Science Angels, and includes venture capital firm Monitor Ventures and previous investors from the Tech Coast Angels.

The round has two representatives on the CODA Board of Directors, Ken Kelley from the Life Science Angels, and Neal Bhadkamkar from Monitor Ventures.

Dr. Robert J. Molinari, CEO of CODA comments, "We are delighted to have LSA and Monitor as our investment partners in CODA."

"LSA, with many experienced life science entrepreneurs as members, is ideally suited to identify and lead this investment. Monitor Ventures, with its extensive links and strategic insight into large biopharmaceutical clients can also greatly assist the company."

Kenneth Kelley said, "Life Science Angels is very excited about CODA's synthetic genes business. We believe their unique Translation Engineering™ solves many problems of protein expression and will be enabling of research in academia and in the biopharmaceutical industry."

Dr. Neal Bhadkamkar said, "Our team was excited by CODA for two reasons: robust, peer reviewed computational technology being applied to a fundamental problem that spans both life-science and industrial markets; and an outstanding team in every part of the company - science, operations, sales and the board."